Cargando…

PET Imaging of PARP Expression Using (18)F-Olaparib

Poly(ADP-ribose) polymerase (PARP) inhibitors are increasingly being studied as cancer drugs, as single agents, or as a part of combination therapies. Imaging of PARP using a radiolabeled inhibitor has been proposed for patient selection, outcome prediction, dose optimization, genotoxic therapy eval...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wilson, Thomas C., Xavier, Mary-Ann, Knight, James, Verhoog, Stefan, Torres, Julia Baguña, Mosley, Michael, Hopkins, Samantha L., Wallington, Sheena, Allen, Phillip D., Kersemans, Veerle, Hueting, Rebekka, Smart, Sean, Gouverneur, Véronique, Cornelissen, Bart
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Society of Nuclear Medicine 2019
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6448459/ https://www.ncbi.nlm.nih.gov/pubmed/30389822 http://dx.doi.org/10.2967/jnumed.118.213223

Ejemplares similares

Correlation between molar activity, injection mass and uptake of the PARP targeting radiotracer [(18)F]olaparib in mouse models of glioma
por: Chan, Chung Ying, et al.
Publicado: (2022)

[(18)F]AZD2461, an Insight on Difference in PARP Binding Profiles for DNA Damage Response PET Imaging
por: Guibbal, Florian, et al.
Publicado: (2020)

Hypoxia Imaging Using PET and SPECT: The Effects of Anesthetic and Carrier Gas on [(64)Cu]-ATSM, [(99m)Tc]-HL91 and [(18)F]-FMISO Tumor Hypoxia Accumulation
por: Kersemans, Veerle, et al.
Publicado: (2011)

Imaging PARP with [(18)F]rucaparib in pancreatic cancer models
por: Chan, Chung Ying, et al.
Publicado: (2022)

Imaging of Claudin-4 in Pancreatic Ductal Adenocarcinoma Using a Radiolabelled Anti-Claudin-4 Monoclonal Antibody
por: Torres, Julia Baguña, et al.
Publicado: (2017)

A Carbon-Fiber Sheet Resistor for MR-, CT-, SPECT-, and PET-Compatible Temperature Maintenance in Small Animals
por: Kersemans, Veerle, et al.
Publicado: (2019)

Radiolabeled cCPE Peptides for SPECT Imaging of Claudin-4 Overexpression in Pancreatic Cancer
por: Torres, Julia Baguña, et al.
Publicado: (2020)

Early Detection in a Mouse Model of Pancreatic Cancer by Imaging DNA Damage Response Signaling
por: Knight, James C., et al.
Publicado: (2020)

Tumor Imaging Using Radiolabeled Matrix Metalloproteinase–Activated Anthrax Proteins
por: Elvina Xavier, Mary-Ann, et al.
Publicado: (2019)

Dual-isotope imaging allows in vivo immunohistochemistry using radiolabelled antibodies in tumours()()
por: Knight, James C., et al.
Publicado: (2019)

Radiofluorination of a highly potent ATM inhibitor as a potential PET imaging agent
por: Fraser, Claudia Rose, et al.
Publicado: (2022)

Immuno-imaging of ICAM-1 in tumours by SPECT
por: Mosley, Michael, et al.
Publicado: (2020)

Imaging DNA Damage Repair In Vivo After (177)Lu-DOTATATE Therapy
por: O’Neill, Edward, et al.
Publicado: (2020)

Targeting the Tumour: Cell Penetrating Peptides for Molecular Imaging and Radiotherapy
por: Kersemans, Veerle, et al.
Publicado: (2010)

Rapamycin sensitizes cancer cells to growth inhibition by the PARP inhibitor olaparib
por: Osoegawa, Atsushi, et al.
Publicado: (2017)

A System-Agnostic, Adaptable and Extensible Animal Support Cradle System for Cardio-Respiratory-Synchronised, and Other, Multi-Modal Imaging of Small Animals
por: Kersemans, Veerle, et al.
Publicado: (2021)

[(123)I]CC1: A PARP-Targeting, Auger Electron–Emitting Radiopharmaceutical for Radionuclide Therapy of Cancer
por: Chan, Chung Ying, et al.
Publicado: (2023)

PARP inhibitor olaparib sensitizes cholangiocarcinoma cells to radiation
por: Mao, Yize, et al.
Publicado: (2018)

(111)In-BnDTPA-F3: an Auger electron-emitting radiotherapeutic agent that targets nucleolin
por: Cornelissen, Bart, et al.
Publicado: (2012)

The PARP inhibitor olaparib enhances the sensitivity of Ewing sarcoma to trabectedin
por: Ordóñez, José Luis, et al.
Publicado: (2015)

Potentiation of Peptide Receptor Radionuclide Therapy by the PARP Inhibitor Olaparib
por: Nonnekens, Julie, et al.
Publicado: (2016)

Manganese-free chow, a refined non-invasive solution to reduce gastrointestinal signal for T(1)-weighted magnetic resonance imaging of the mouse abdomen
por: Kersemans, Veerle, et al.
Publicado: (2019)

ATM-Deficient Colorectal Cancer Cells Are Sensitive to the PARP Inhibitor Olaparib()
por: Wang, Chen, et al.
Publicado: (2017)

Correction: The PARP inhibitor olaparib enhances the sensitivity of Ewing sarcoma to trabectedin
por: Ordóñez, José Luis, et al.
Publicado: (2017)

Olaparib‐Based Photoaffinity Probes for PARP‐1 Detection in Living Cells
por: Voorneveld, Jim, et al.
Publicado: (2020)

PARP inhibitor Olaparib increases the sensitization to radiotherapy in FaDu cells
por: Liu, Chuan, et al.
Publicado: (2020)

Imaging of translocator protein upregulation is selective for pro‐inflammatory polarized astrocytes and microglia
por: Pannell, Maria, et al.
Publicado: (2019)

Ultrasound-mediated cavitation enhances the delivery of an EGFR-targeting liposomal formulation designed for chemo-radionuclide therapy
por: Thomas, Eloise, et al.
Publicado: (2019)

An evaluation in vitro of PARP-1 inhibitors, rucaparib and olaparib, as radiosensitisers for the treatment of neuroblastoma
por: Nile, Donna L., et al.
Publicado: (2016)

The PARP inhibitor olaparib potentiates the effect of the DNA damaging agent doxorubicin in osteosarcoma
por: Park, Hye Jeong, et al.
Publicado: (2018)

PARP inhibitor olaparib sensitizes esophageal carcinoma cells to fractionated proton irradiation
por: Kageyama, Shun-ichiro, et al.
Publicado: (2020)

Recurrent Cervical Cancer Treated Successfully with Single-Agent PARP-Inhibitor, Olaparib
por: Gross, Maya, et al.
Publicado: (2022)

Olaparib increases the therapeutic index of hemithoracic irradiation compared with hemithoracic irradiation alone in a mouse lung cancer model
por: Jiang, Yanyan, et al.
Publicado: (2021)

Closing the gap between (19)F and (18)F chemistry
por: Ajenjo, Javier, et al.
Publicado: (2021)

Correction to: Closing the gap between (19)F and (18)F chemistry
por: Ajenjo, Javier, et al.
Publicado: (2022)

Cross-platform pathway-based analysis identifies markers of response to the PARP inhibitor olaparib
por: Daemen, Anneleen, et al.
Publicado: (2012)

Discovery of a potent olaparib–chlorambucil hybrid inhibitor of PARP1 for the treatment of cancer
por: Qin, Hongyu, et al.
Publicado: (2023)

A Model System to Explore the Detection Limits of Antibody-Based Immuno-SPECT Imaging of Exclusively Intranuclear Epitopes
por: Veal, Mathew, et al.
Publicado: (2021)

The PARP inhibitor Olaparib disrupts base excision repair of 5-aza-2′-deoxycytidine lesions
por: Orta, Manuel Luis, et al.
Publicado: (2014)

JF-305, a pancreatic cancer cell line is highly sensitive to the PARP inhibitor olaparib
por: YANG, XUELI, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_pclosgh7ch20jiureq08hfvetn